Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Alumis Inc. Common StockNASDAQ: ALMS

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt remains negative

Q2 FY2026 net debt was -$27.28M, compared with -$112.98M a year earlier.

Context

  • Net debt amounted to 4.9% of total assets at the end of Q2 FY2026, down 13.6 pp from a year earlier.
  • Net debt grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +75.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$27.28M+3.3% QoQ
Last fiscal yearDec 2025
-$52.76M+62.0% YoY
Year agoJun 2025
-$112.98M+75.9% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+75.9%——
1 year+62.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(52.76M) USD
Year-over-year change
+62.0%

Net Debt vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +75.9% is the 3rd highest of 9, against a peer median of +36.9%.
  • Net debt amounts to 4.9% of total assets for ALMS, versus a peer median of 22.7%.
ALMS Competitors
Net Debt for ALMS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANABAnaptysBio, Inc.Mar 2026$28.89M USD+134.8%—8.8%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$21.31M USD+38.9%-9.4%4.2%
TLSATiziana Life Sciences LtdDec 2025-$3.55M USD+1.8%—30.9%
ARTVArtiva Biotherapeutics, Inc.Mar 2026-$10.69M USD+34.8%—10.1%
IFRXInflaRx N.V.Mar 2026-€14.19M EUR+69.5%—29.0%
AVTXAvalo Therapeutics, Inc.Mar 2026-$22.66M USD+81.8%—22.7%
ACRSAclaris Therapeutics, Inc.Mar 2026-$26.68M USD+4.3%—13.4%
ALMSAlumis Inc. Common StockJun 2026-$27.28M USD+75.9%—4.9%
ALDXAldeyra Therapeutics, Inc.Mar 2026-$49.49M USD-42.3%—74.4%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025-€128.26M EUR——77.4%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ALMS) —+36.9%-9.4%22.7%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.61M46M169.53M89.67M
Short-term Investments67.26M2.96M118.74M218.83M
Net Receivables500K722K1.81M2.08M
Inventory0000
Other Current Assets206K208K762K7.65M
Total Current Assets102.56M53.36M306.19M318.23M
Property, Plant & Equipment (Net)4.48M35.22M33.69M35.16M
Goodwill0000
Intangible Assets00050.96M
Long-term Investments0000
Tax Assets0000
Other Non-current Assets1.14M1.03M1.11M7.59M
Total Non-current Assets5.61M36.26M34.8M93.71M
Total Assets108.17M89.61M340.99M411.94M
Account Payables1.72M1.12M9.62M10.11M
Short-term Debt0004.67M
Tax Payables0000
Deferred Revenue0001.46M
Other Current Liabilities3.58M5.59M7.77M57.08M
Total Current Liabilities13.35M20.87M50.91M73.32M
Long-term Debt0000
Deferred Tax Liabilities0002.14M
Deferred Revenue (Non-current)0002.61M
Other Non-current Liabilities289.59M377.14M814K330K
Total Non-current Liabilities290.06M408M29.98M37.33M
Total Liabilities303.41M428.87M80.89M110.64M
Common Stock1K1K4K9K
Retained Earnings(209.33M)(364.32M)(658.55M)(901.88M)
Accumulated OCI(127K)2K40K188K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(195.24M)(339.26M)260.1M301.3M
Total Debt1.78M32.58M30.72M36.91M
Net Debt(23.83M)(13.42M)(138.8M)(52.76M)

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.